First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
First In Human, Multi-Center Open-Label Randomized Trial to Assess Safety of Rincell-1 Otic Neural Progenitor Cell-Based Therapy and Standard Care vs Standard Care Alone, in Adults With Neural Hearing Loss Eligible for Cochlear Implantation
Sponsor: King's College London
Listed as NCT07032038, this PHASE1/PHASE2 trial focuses on Auditory Neuropathy and Presbyacusis and remains actively recruiting participants. Sponsored by King's College London, it has been updated 4 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Mar 2026 — Present [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Oct 2025 — Mar 2026 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Aug 2025 — Oct 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- King's College London
- Rinri Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .